SOURCE: Kraig Biocraft Laboratories, Inc.

December 08, 2011 06:05 ET

Kraig Biocraft Laboratories Announces Filing of International Patent Application for Spider-Silk and Transgenic Silkworm Technologies

LANSING, MI--(Marketwire - Dec 8, 2011) - Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (PINKSHEETS: KBLB) is very pleased to announce that the University of Notre Dame has filed an international patent application for spider-silk technologies developed in collaboration with Kraig Biocraft Laboratories.

The international patent application was filed in Geneva, Switzerland pursuant to the International Patent Cooperation Treaty. The patent application includes the essential spider-silk and transgenic silkworm technologies which the Company and University have developed cooperatively.

The technologies described in the international patent application are also the subject of the exclusive commercial license agreement which the Company recently signed with the University. The spider-silk technology defined in the application includes the product which the Company refers to as Monster Silk, as well as genetic engineering methodologies and product utilities.

"The filing of this international patent application is a major milestone for the commercialization of recombinant spider-silk and of Monster Silk most particularly," said the Company's founder and CEO, Kim K Thompson. "Now that the international application has been filed, we are in a position to move aggressively with product and commercialization ramp up. It also places us in a stronger position for corporate engagement and business development."

"The commercial license agreement which the Company signed last month with the University covers these technologies and gives Kraig Biocraft Laboratories the exclusive global right to market the products and technologies described in the patent application," continued Thompson. "We see this filing in Geneva, coupled with our license agreements with the University of Wyoming, the University of Notre Dame and our license agreement with Sigma-Aldrich, as the corner stones of our expanding intellectual property portfolio. We feel well armed as we move forward to bring recombinant spider-silk to market."

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. ( is a fully reporting biotechnology company that recently achieved a series of scientific breakthroughs, with implications for the global textile industry.

Cautionary Statement Regarding Forward-Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "develops," "researching," "research," "potential," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

Contact Information